Quarterly report pursuant to Section 13 or 15(d)

Debt - Additional Information (Details)

v3.20.2
Debt - Additional Information (Details)
3 Months Ended 9 Months Ended
Nov. 02, 2020
USD ($)
$ / shares
shares
Oct. 27, 2020
USD ($)
$ / shares
shares
Sep. 08, 2020
USD ($)
Debtinstrument
$ / shares
shares
Apr. 30, 2020
USD ($)
Jan. 21, 2020
USD ($)
Debtinstrument
$ / shares
shares
Apr. 27, 2018
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
Debt Instrument [Line Items]                  
Accretion of debt discounts and deferred financing costs               $ 7,818,000 $ 243,000
Financing transaction costs             $ 685,000 $ 2,815,000  
Ordinary Shares                  
Debt Instrument [Line Items]                  
Number of warrants to purchase ordinary shares | shares           19,890 19,890 19,890  
Loan and Security Agreement | Silicon Valley Bank (SVB)                  
Debt Instrument [Line Items]                  
Loan and security agreement entered date               Apr. 27, 2018  
Funded amount under agreement           $ 15,000,000      
Remaining borrowing facility available date           Oct. 31, 2019      
Maximum amount available under agreement           $ 30,000,000      
Non-utilization fee percentage of undrawn principal amount           1.50%      
Frequency of amortization payments               Monthly  
Date of first required payment of initial draw           Nov. 01, 2019      
Minimum fixed interest rate per annum           8.31%      
Final interest rate payment on outstanding principal           4.20%      
Principal and interest payment, maturity date           Mar. 01, 2022      
Final payment fee           $ 630,000      
Prepayment fee in first year           4.00%      
Prepayment fee in second year           3.00%      
Prepayment fee thereafter           2.00%      
Principal payment during the period           $ 4,655,000      
Effective annual interest rate on outstanding debt             12.51% 12.51%  
Interest expense               $ 1,091,000 1,310,000
Accretion of debt discounts and deferred financing costs               $ 324,000 $ 243,000
Loan and Security Agreement | Silicon Valley Bank (SVB) | Wall Street Journal Prime Rate                  
Debt Instrument [Line Items]                  
Basis spread on interest rate           3.89%      
Loan and Security Agreement | Silicon Valley Bank (SVB) | Maximum                  
Debt Instrument [Line Items]                  
Maximum amount available under second draw           $ 15,000,000      
Silicon Valley Bank and Life Sciences Fund II LLC                  
Debt Instrument [Line Items]                  
Percentage of purchase additional ordinary shares equal to term loan divided by applicable exercise price           2.50%      
Silicon Valley Bank and Life Sciences Fund II LLC | Series B Convertible Preferred Shares                  
Debt Instrument [Line Items]                  
Number of warrants to purchase ordinary shares | shares           19,890 19,890 19,890  
Warrants to purchase ordinary shares, exercise price | $ / shares           $ 18.85 $ 18.85 $ 18.85  
2025 Exchangeable Notes                  
Debt Instrument [Line Items]                  
Interest expense             $ 860,000 $ 2,339,000  
Accretion of debt discounts and deferred financing costs             2,062,000 $ 5,665,000  
Debt instrument, payment terms               The Company will be required to pay the holder of the Exchangeable Notes the greater of three times the outstanding principal amount of such Exchangeable Note and the consideration that would be received by the holder of such Exchangeable Note in connection with such Fundamental Change if the holder had exchanged its note for ordinary shares immediately prior to the consummation of such Fundamental Change, plus any accrued and unpaid interest.  
Fair value of derivative liability         $ 27,038,000        
Fair value of derivative liability related to rights offering         82,000        
Financing transaction costs               $ 2,815,000  
Financing transaction costs, capitalized             2,814,000 2,814,000  
2025 Exchangeable Notes | Subsequent Event                  
Debt Instrument [Line Items]                  
Debt instrument, shares embedded within each unit, shares | shares 1,286.1845 1,000              
Debt instrument, shares embedded within each unit, value $ 1,000 $ 1,000              
Debt instrument, shares embedded within each unit, exchange price | $ / shares $ 0.7775 $ 1.00              
2025 Exchangeable Notes | Private Placement                  
Debt Instrument [Line Items]                  
Aggregate principal amount     $ 200,000   $ 51,600,000        
Debt instrument interest rate     6.50%   6.50%        
Debt instrument price per unit     $ 1,000   $ 1,000        
RLNs | Private Placement                  
Debt Instrument [Line Items]                  
Aggregate principal amount     $ 20,000   $ 100,000        
Number of debt instruments within each notes | Debtinstrument     50   50        
Securities | Private Placement                  
Debt Instrument [Line Items]                  
Debt instrument price per unit     $ 1,000   $ 1,000        
Debt instrument, shares embedded within each unit, shares | shares     1,000   1,000        
Debt instrument, shares embedded within each unit, value     $ 1,000   $ 1,000        
Debt instrument, shares embedded within each unit, exchange price | $ / shares     $ 1.00   $ 1.00        
Securities | Private Placement | Subsequent Event                  
Debt Instrument [Line Items]                  
Debt instrument, shares embedded within each unit, shares | shares 1,286.1845                
Debt instrument, shares embedded within each unit, value $ 1,000                
Debt instrument, shares embedded within each unit, exchange price | $ / shares $ 0.7775                
Paycheck Protection Program                  
Debt Instrument [Line Items]                  
Interest expense             $ 1,000 $ 3,000  
Paycheck Protection Program | Silicon Valley Bank (SVB) | Iterum Therapeutics US Limited                  
Debt Instrument [Line Items]                  
Aggregate principal amount       $ 744,000          
Debt instrument interest rate       1.00%          
Debt instrument maturity period       2 years          
Minimum percentage of loan proceeds used for payroll costs       60.00%          
Debt instrument, description       Under the terms of the agreement, there shall be no payments due by the Company until the later of the date the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan on the last day of the Deferral Period by the maturity date. Under the terms of the Program, the SBA will forgive the portion of loan proceeds used for U.S. payroll costs and other designated operating expenses for up to 24 weeks, provided at least 60% of the loan proceeds are used for U.S. payroll costs. The Company incurred qualifying payroll costs and other operating expenses in the 24 weeks following April 30, 2020, and has requested forgiveness for a portion of the PPP loan from the Lender       Under the terms of the agreement, there shall be no payments due by the Company until the later of the date the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the note on the last day of the Deferral Period by the maturity date. Under the terms of the Program, the SBA will forgive the portion of loan proceeds used for payroll costs and other designated operating expenses for up to 24 weeks, provided at least 60% of the loan proceeds are used for payroll costs. The Company incurred qualifying payroll costs and other operating expenses in the 24 weeks from April 30, 2020, and has requested forgiveness for a portion of the loan from the Lender